Abstract 1718
Background
Preliminary data from the TRAP study demonstrated feasibility of neoadjuvant chemoradiation (nCRT) with trastuzumab and pertuzumab. Here, we present updated survival results with propensity score matching, including potential predictive biomarkers for response to this treatment.
Methods
Patients (pts) with HER2+ resectable esophageal adenocarcinoma (EAC) received nCRT with trastuzumab and pertuzumab (Schokker et al, JCO 2018 suppl. 4057). Survival data was compared with patients not receiving study medication in the Dutch Cancer Registry, using propensity score matching (1:4) based on a logistical regression model, matching for baseline demographic and clinical characteristics. HER2 status was not included as a matching variable, since it was unknown in the majority of pts in the matched cohort. Associations between baseline F-FDG uptake on PET scans, measured by the maximum standardized uptake value (SUVmax), or ΔSUVmax and pathological complete response (pCR) were assessed. Furthermore, expression of HER2 and growth factor receptor-bound protein (Grb)7 was assessed by immunohistochemistry on baseline biopsies. Results were correlated with pCR and survival.
Results
40 pts were enrolled and pCR was seen in 34%. Progression-free survival (PFS) rates at 1 and 3 years were 83% and 72%, respectively, with 1- and 3-year overall survival (OS) rates of 90% and 71% (median follow-up 32.1 months). A statistically significant difference in OS was observed for nCRT with trastuzumab and pertuzumab compared to nCRT (3-year OS rate 71% vs 54%, p = 0.039). Baseline and post-treatment PET scans were available for 40 and 34 pts, respectively. Baseline SUVmax was not predictive for recurrence or death, neither did ΔSUVmax correlate with pCR (p > 0.05). HER2 3+ pts and pts with Grb7+ tumours at baseline demonstrated a significantly better response to treatment (p = 0.016 respectively p = 0.007).
Conclusions
Compared to a propensity score matched cohort receiving nCRT, OS of pts with resectable HER2+ EAC receiving nCRT with trastuzumab and pertuzumab is statistically better. Grb7 and HER2 3+ are potential predictive biomarkers for response to this treatment.
Clinical trial identification
NCT02120911 April 23, 2014.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Roche.
Disclosure
R.H.A. Verhoeven: Research grant / Funding (self): Roche; Research grant / Funding (self): Bristol-Myers Squibb. M. van Oijen: Research grant / Funding (institution): Roche; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Nordic. G.A.P. Hospers: Advisory / Consultancy, Payment to institution: Amgen; Advisory / Consultancy, Payment to institution: Roche; Advisory / Consultancy, Payment to institution: MSD; Advisory / Consultancy, Research grant / Funding (institution), Payment to institution: BMS; Advisory / Consultancy, Payment to institution: Pfizer; Advisory / Consultancy, Payment to institution: Novartis; Research grant / Funding (institution), Payment to institution: Seerave. M. Bijlsma: Research grant / Funding (institution): Celgene; Advisory / Consultancy: Servier. M.I. van Berge Henegouwen: Honoraria (institution), Research grant / Funding (institution): Stryker; Honoraria (institution), Research grant / Funding (institution): Olympus; Honoraria (institution), Advisory / Consultancy: Medtronic; Honoraria (institution), Research grant / Funding (institution): Mylan. H.W.M. van Laarhoven: Honoraria (self), Advisory / Consultancy: Lilly/ImClone; Advisory / Consultancy, Research grant / Funding (institution): Nordic Group; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution): Bayer Schering Pharma; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Janssen-Cilag; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Philips Healthcare; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Merck Sharp & Dohme. All other authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract